{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:28:01Z","timestamp":1792618081336,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-20749-5","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:44:36Z","timestamp":1761039876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Histone deacetylase inhibitors sensitize glioblastoma models to temozolomide and reprogram immunosuppressive myeloid cells"],"prefix":"10.1038","volume":"15","author":[{"given":"Golnaz Asaadi","family":"Tehrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca N.","family":"Kubick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksym","family":"Zarodniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenal","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"20749_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fonc.2016.00016","volume":"6","author":"A Liu","year":"2016","unstructured":"Liu, A., Hou, C., Chen, H., Zong, X. & Zong, P. Genetics and epigenetics of glioblastoma: applications and overall incidence of IDH1 mutation. Front. Oncol. 6, 16. https:\/\/doi.org\/10.3389\/fonc.2016.00016 (2016).","journal-title":"Front. Oncol."},{"key":"20749_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.semcancer.2020.12.015","volume":"83","author":"MS Uddin","year":"2022","unstructured":"Uddin, M. S. et al. Epigenetics of glioblastoma multiforme: from molecular mechanisms to therapeutic approaches. Sem. Cancer Biol. 83, 100\u2013120. https:\/\/doi.org\/10.1016\/j.semcancer.2020.12.015 (2022). https:\/\/doi.org\/https:\/\/doi.org\/","journal-title":"Sem. Cancer Biol."},{"key":"20749_CR3","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3389\/fonc.2018.00448","volume":"8","author":"M Romani","year":"2018","unstructured":"Romani, M., Pistillo, M. P. & Banelli, B. Epigenetic targeting of glioblastoma. Front. Oncol. 8, 448. https:\/\/doi.org\/10.3389\/fonc.2018.00448 (2018).","journal-title":"Front. Oncol."},{"key":"20749_CR4","doi-asserted-by":"publisher","unstructured":"Hassell, K. N. Histone deacetylases and their inhibitors in cancer epigenetics. Diseases 7. https:\/\/doi.org\/10.3390\/diseases7040057 (2019).","DOI":"10.3390\/diseases7040057"},{"key":"20749_CR5","doi-asserted-by":"publisher","unstructured":"Li, G., Tian, Y. & Zhu, W. G. The roles of histone deacetylases and their inhibitors in cancer therapy. Front. Cell. Dev. Biology. 8. https:\/\/doi.org\/10.3389\/fcell.2020.576946 (2020).","DOI":"10.3389\/fcell.2020.576946"},{"key":"20749_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","volume":"143","author":"P Bose","year":"2014","unstructured":"Bose, P., Dai, Y. & Grant, S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol. Ther. 143, 323\u2013336. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.04.004 (2014).","journal-title":"Pharmacol. Ther."},{"key":"20749_CR7","doi-asserted-by":"publisher","first-page":"14639","DOI":"10.1073\/pnas.1008522107","volume":"107","author":"JH Lee","year":"2010","unstructured":"Lee, J. H., Choy, M. L., Ngo, L., Foster, S. S. & Marks, P. A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl. Acad. Sci. U S A. 107, 14639\u201314644. https:\/\/doi.org\/10.1073\/pnas.1008522107 (2010).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"20749_CR8","doi-asserted-by":"publisher","first-page":"e1435","DOI":"10.1038\/cddis.2014.412","volume":"5","author":"M Cornago","year":"2014","unstructured":"Cornago, M. et al. Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis. 5, e1435\u2013e1435. https:\/\/doi.org\/10.1038\/cddis.2014.412 (2014).","journal-title":"Cell Death Dis."},{"key":"20749_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2008.03.037","volume":"269","author":"JS Carew","year":"2008","unstructured":"Carew, J. S., Giles, F. J. & Nawrocki, S. T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269, 7\u201317. https:\/\/doi.org\/10.1016\/j.canlet.2008.03.037 (2008).","journal-title":"Cancer Lett."},{"key":"20749_CR10","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s12032-014-0985-5","volume":"31","author":"P Bezecny","year":"2014","unstructured":"Bezecny, P. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience. Med. Oncol. 31, 985. https:\/\/doi.org\/10.1007\/s12032-014-0985-5 (2014).","journal-title":"Med. Oncol."},{"key":"20749_CR11","doi-asserted-by":"publisher","unstructured":"Lo Cascio, C. et al. Quisinostat is a brain-penetrant radiosensitizer in glioblastoma. JCI Insight. 8. https:\/\/doi.org\/10.1172\/jci.insight.167081 (2023).","DOI":"10.1172\/jci.insight.167081"},{"key":"20749_CR12","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/molecules20033898","volume":"20","author":"M Mottamal","year":"2015","unstructured":"Mottamal, M., Zheng, S., Huang, T. L. & Wang, G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20, 3898\u20133941. https:\/\/doi.org\/10.3390\/molecules20033898 (2015).","journal-title":"Molecules"},{"key":"20749_CR13","doi-asserted-by":"publisher","first-page":"E967","DOI":"10.1093\/neuros\/nyz218","volume":"85","author":"N Sanai","year":"2019","unstructured":"Sanai, N. Phase 0 clinical trial strategies for the neurosurgical oncologist. Neurosurgery 85, E967\u2013e974. https:\/\/doi.org\/10.1093\/neuros\/nyz218 (2019).","journal-title":"Neurosurgery"},{"key":"20749_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","volume":"39","author":"R Chen","year":"2020","unstructured":"Chen, R. et al. The application of histone deacetylases inhibitors in glioblastoma. J. Exp. Clin. Cancer Res. 39, 138. https:\/\/doi.org\/10.1186\/s13046-020-01643-6 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"20749_CR15","first-page":"166","volume":"3","author":"HJ Kim","year":"2011","unstructured":"Kim, H. J. & Bae, S. C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl Res. 3, 166\u2013179 (2011).","journal-title":"Am. J. Transl Res."},{"key":"20749_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","volume":"17","author":"MQ Shi","year":"2024","unstructured":"Shi, M. Q. et al. Advances in targeting histone deacetylase for treatment of solid tumors. J. Hematol. Oncol. 17, 37. https:\/\/doi.org\/10.1186\/s13045-024-01551-8 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"20749_CR17","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","volume":"13","author":"T Liang","year":"2023","unstructured":"Liang, T. et al. Targeting histone deacetylases for cancer therapy: trends and challenges. Acta Pharm. Sin B. 13, 2425\u20132463. https:\/\/doi.org\/10.1016\/j.apsb.2023.02.007 (2023).","journal-title":"Acta Pharm. Sin B"},{"key":"20749_CR18","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.bpj.2024.03.034","volume":"123","author":"K Onwudiwe","year":"2024","unstructured":"Onwudiwe, K. et al. Single-cell mechanical assay unveils viscoelastic similarities in normal and neoplastic brain cells. Biophys. J. 123, 1098\u20131105. https:\/\/doi.org\/10.1016\/j.bpj.2024.03.034 (2024).","journal-title":"Biophys. J."},{"key":"20749_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41551-018-0334-7","volume":"3","author":"G Seano","year":"2019","unstructured":"Seano, G. et al. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nat. Biomed. Eng. 3, 230\u2013245. https:\/\/doi.org\/10.1038\/s41551-018-0334-7 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"20749_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262 (2001).","journal-title":"Methods"},{"key":"20749_CR21","doi-asserted-by":"publisher","first-page":"11239","DOI":"10.18632\/oncotarget.14496","volume":"8","author":"R Wong","year":"2017","unstructured":"Wong, R., Turlova, E., Feng, Z. P., Rutka, J. T. & Sun, H. S. Activation of TRPM7 by Naltriben enhances migration and invasion of glioblastoma cells. Oncotarget 8, 11239\u201311248. https:\/\/doi.org\/10.18632\/oncotarget.14496 (2017).","journal-title":"Oncotarget"},{"key":"20749_CR22","doi-asserted-by":"publisher","first-page":"102307","DOI":"10.1016\/j.ceca.2020.102307","volume":"92","author":"R Wong","year":"2020","unstructured":"Wong, R. et al. Inhibition of TRPM7 with Waixenicin A reduces glioblastoma cellular functions. Cell. Calcium. 92, 102307. https:\/\/doi.org\/10.1016\/j.ceca.2020.102307 (2020). https:\/\/doi.org\/https:\/\/doi.org\/","journal-title":"Cell. Calcium"},{"key":"20749_CR23","doi-asserted-by":"publisher","first-page":"16321","DOI":"10.18632\/oncotarget.3872","volume":"6","author":"WL Chen","year":"2015","unstructured":"Chen, W. L. et al. Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion. Oncotarget 6, 16321\u201316340. https:\/\/doi.org\/10.18632\/oncotarget.3872 (2015).","journal-title":"Oncotarget"},{"key":"20749_CR24","doi-asserted-by":"publisher","unstructured":"De Leo, A., Ugolini, A. & Veglia, F. Myeloid cells in glioblastoma microenvironment. Cells 10. https:\/\/doi.org\/10.3390\/cells10010018 (2020).","DOI":"10.3390\/cells10010018"},{"key":"20749_CR25","doi-asserted-by":"publisher","first-page":"9123","DOI":"10.18632\/oncotarget.13265","volume":"8","author":"SA Choi","year":"2017","unstructured":"Choi, S. A. et al. A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma. Oncotarget 8, 9123\u20139133. https:\/\/doi.org\/10.18632\/oncotarget.13265 (2017).","journal-title":"Oncotarget"},{"key":"20749_CR26","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1002\/cncr.34974","volume":"129","author":"R Parveen","year":"2023","unstructured":"Parveen, R., Harihar, D. & Chatterji, B. P. Recent histone deacetylase inhibitors in cancer therapy. Cancer 129, 3372\u20133380. https:\/\/doi.org\/10.1002\/cncr.34974 (2023).","journal-title":"Cancer"},{"key":"20749_CR27","first-page":"615","volume":"35","author":"P Lee","year":"2015","unstructured":"Lee, P. et al. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Res. 35, 615\u2013625 (2015).","journal-title":"Anticancer Res."},{"key":"20749_CR28","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.4161\/auto.25664","volume":"9","author":"MT Chiao","year":"2013","unstructured":"Chiao, M. T., Cheng, W. Y., Yang, Y. C., Shen, C. C. & Ko, J. L. Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. Autophagy 9, 1509\u20131526. https:\/\/doi.org\/10.4161\/auto.25664 (2013).","journal-title":"Autophagy"},{"key":"20749_CR29","doi-asserted-by":"publisher","first-page":"722754","DOI":"10.3389\/fonc.2021.722754","volume":"11","author":"HC Tsai","year":"2021","unstructured":"Tsai, H. C. et al. Valproic acid enhanced Temozolomide-Induced anticancer activity in human glioma through the p53-PUMA apoptosis pathway. Front. Oncol. 11, 722754. https:\/\/doi.org\/10.3389\/fonc.2021.722754 (2021).","journal-title":"Front. Oncol."},{"key":"20749_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/sj.onc.1209785","volume":"26","author":"WP Roos","year":"2007","unstructured":"Roos, W. P. et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26, 186\u2013197. https:\/\/doi.org\/10.1038\/sj.onc.1209785 (2007).","journal-title":"Oncogene"},{"key":"20749_CR31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl. J. Med. 352, 987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330 (2005).","journal-title":"N Engl. J. Med."},{"key":"20749_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jbiotec.2010.01.012","volume":"148","author":"F Hirschhaeuser","year":"2010","unstructured":"Hirschhaeuser, F. et al. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 148, 3\u201315. https:\/\/doi.org\/10.1016\/j.jbiotec.2010.01.012 (2010). https:\/\/doi.org\/https:\/\/doi.org\/","journal-title":"J. Biotechnol."},{"key":"20749_CR33","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","volume":"16","author":"M Duvic","year":"2007","unstructured":"Duvic, M. & Vu, J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin. Investig. Drugs. 16, 1111\u20131120. https:\/\/doi.org\/10.1517\/13543784.16.7.1111 (2007).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"20749_CR34","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/neuonc\/nox161","volume":"20","author":"E Galanis","year":"2018","unstructured":"Galanis, E. et al. Phase I\/II trial of Vorinostat combined with Temozolomide and radiation therapy for newly diagnosed glioblastoma: results of alliance N0874\/ABTC 02. Neuro Oncol. 20, 546\u2013556. https:\/\/doi.org\/10.1093\/neuonc\/nox161 (2018).","journal-title":"Neuro Oncol."},{"key":"20749_CR35","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1200\/jco.2008.19.0694","volume":"27","author":"E Galanis","year":"2009","unstructured":"Galanis, E. et al. Phase II trial of Vorinostat in recurrent glioblastoma multiforme: a North central cancer treatment group study. J. Clin. Oncol. 27, 2052\u20132058. https:\/\/doi.org\/10.1200\/jco.2008.19.0694 (2009).","journal-title":"J. Clin. Oncol."},{"key":"20749_CR36","unstructured":"Diss, E. et al. Vorinostat(SAHA) promotes Hyper-Radiosensitivity in wild type p53 human glioblastoma cells. J Clin. Oncol. Res 2 (2014)."},{"key":"20749_CR37","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1177\/10600280211055508","volume":"56","author":"J Guo","year":"2022","unstructured":"Guo, J. et al. Valproic acid after neurosurgery induces elevated risk of liver injury: A prospective nested Case-Control study. Ann. Pharmacother. 56, 888\u2013897. https:\/\/doi.org\/10.1177\/10600280211055508 (2022).","journal-title":"Ann. Pharmacother"},{"key":"20749_CR38","doi-asserted-by":"publisher","first-page":"14666","DOI":"10.18632\/oncotarget.14716","volume":"8","author":"JH Tseng","year":"2017","unstructured":"Tseng, J. H. et al. Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. Oncotarget 8, 14666\u201314679. https:\/\/doi.org\/10.18632\/oncotarget.14716 (2017).","journal-title":"Oncotarget"},{"key":"20749_CR39","doi-asserted-by":"publisher","first-page":"35004","DOI":"10.18632\/oncotarget.5253","volume":"6","author":"D Thotala","year":"2015","unstructured":"Thotala, D. et al. Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells. Oncotarget 6, 35004\u201335022. https:\/\/doi.org\/10.18632\/oncotarget.5253 (2015).","journal-title":"Oncotarget"},{"key":"20749_CR40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41419-020-2586-x","volume":"11","author":"J Auzmendi-Iriarte","year":"2020","unstructured":"Auzmendi-Iriarte, J. et al. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma. Cell Death Dis. 11, 417. https:\/\/doi.org\/10.1038\/s41419-020-2586-x (2020).","journal-title":"Cell Death Dis."},{"key":"20749_CR41","doi-asserted-by":"publisher","unstructured":"Garrett, M. et al. HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma. Sci. Rep. 13. https:\/\/doi.org\/10.1038\/s41598-023-33889-3 (2023).","DOI":"10.1038\/s41598-023-33889-3"},{"key":"20749_CR42","doi-asserted-by":"publisher","unstructured":"Urdiciain, A. et al. Silencing of histone deacetylase 6 decreases cellular malignancy and contributes to primary cilium Restoration, Epithelial-to-Mesenchymal transition Reversion, and autophagy Inhibition in glioblastoma cell lines. Biology (Basel). 10. https:\/\/doi.org\/10.3390\/biology10060467 (2021).","DOI":"10.3390\/biology10060467"},{"key":"20749_CR43","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canlet.2016.06.001","volume":"379","author":"Z Wang","year":"2016","unstructured":"Wang, Z. et al. HDAC6 promotes cell proliferation and confers resistance to Temozolomide in glioblastoma. Cancer Lett. 379, 134\u2013142. https:\/\/doi.org\/10.1016\/j.canlet.2016.06.001 (2016).","journal-title":"Cancer Lett."},{"key":"20749_CR44","doi-asserted-by":"crossref","unstructured":"Spallotta, F. & Illi, B. The role of HDAC6 in glioblastoma multiforme: A new avenue to therapeutic interventions? Biomedicines 12 (2024).","DOI":"10.3390\/biomedicines12112631"},{"key":"20749_CR45","doi-asserted-by":"publisher","first-page":"216121","DOI":"10.1016\/j.canlet.2023.216121","volume":"559","author":"B Moran","year":"2023","unstructured":"Moran, B., Davern, M., Reynolds, J. V., Donlon, N. E. & Lysaght, J. The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy. Cancer Lett. 559, 216121. https:\/\/doi.org\/10.1016\/j.canlet.2023.216121 (2023).","journal-title":"Cancer Lett."},{"key":"20749_CR46","doi-asserted-by":"publisher","unstructured":"Li, Y. & Seto, E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect. Med. 6. https:\/\/doi.org\/10.1101\/cshperspect.a026831 (2016).","DOI":"10.1101\/cshperspect.a026831"},{"key":"20749_CR47","doi-asserted-by":"publisher","unstructured":"Hoffmann, M. J., Meneceur, S., Hommel, K., Schulz, W. A. & Niegisch, G. Downregulation of cell cycle and checkpoint genes by class I HDAC inhibitors limits synergism with G2\/M checkpoint inhibitor MK-1775 in bladder cancer cells. Genes (Basel). 12. https:\/\/doi.org\/10.3390\/genes12020260 (2021).","DOI":"10.3390\/genes12020260"},{"key":"20749_CR48","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/1078-0432.ccr-03-0100","volume":"10","author":"N Takai","year":"2004","unstructured":"Takai, N. et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin. Cancer Res. 10, 1141\u20131149. https:\/\/doi.org\/10.1158\/1078-0432.ccr-03-0100 (2004).","journal-title":"Clin. Cancer Res."},{"key":"20749_CR49","doi-asserted-by":"publisher","unstructured":"Mrakovcic, M., Kleinheinz, J. & Fr\u00f6hlich, L. F. Histone deacetylase Inhibitor-Induced autophagy in tumor cells: implications for p53. Int. J. Mol. Sci. 18. https:\/\/doi.org\/10.3390\/ijms18091883 (2017).","DOI":"10.3390\/ijms18091883"},{"key":"20749_CR50","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1161\/circulationaha.112.103176","volume":"126","author":"L Zhao","year":"2012","unstructured":"Zhao, L. et al. Histone deacetylation Inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126, 455\u2013467. https:\/\/doi.org\/10.1161\/circulationaha.112.103176 (2012).","journal-title":"Circulation"},{"key":"20749_CR51","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1177\/2472555218775055","volume":"23","author":"V Quereda","year":"2018","unstructured":"Quereda, V. et al. A cytotoxic Three-Dimensional-Spheroid, High-Throughput assay using Patient-Derived glioma stem cells. SLAS Discov. 23, 842\u2013849. https:\/\/doi.org\/10.1177\/2472555218775055 (2018).","journal-title":"SLAS Discov"},{"key":"20749_CR52","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/1078-0432.Ccr-17-2256","volume":"24","author":"M Kogiso","year":"2018","unstructured":"Kogiso, M. et al. Concurrent Inhibition of neurosphere and monolayer cells of pediatric glioblastoma by Aurora A inhibitor MLN8237 predicted survival extension in PDOX models. Clin. Cancer Res. 24, 2159\u20132170. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2256 (2018).","journal-title":"Clin. Cancer Res."},{"key":"20749_CR53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11060-019-03107-0","volume":"142","author":"A Musah-Eroje","year":"2019","unstructured":"Musah-Eroje, A. & Watson, S. A novel 3D in vitro model of glioblastoma reveals resistance to Temozolomide which was potentiated by hypoxia. J. Neurooncol. 142, 231\u2013240. https:\/\/doi.org\/10.1007\/s11060-019-03107-0 (2019).","journal-title":"J. Neurooncol"},{"key":"20749_CR54","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1073\/pnas.1525360113","volume":"113","author":"J Kloepper","year":"2016","unstructured":"Kloepper, J. et al. Ang-2\/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc. Natl. Acad. Sci. 113, 4476\u20134481. https:\/\/doi.org\/10.1073\/pnas.1525360113 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"20749_CR55","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1073\/pnas.1525349113","volume":"113","author":"TE Peterson","year":"2016","unstructured":"Peterson, T. E. et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc. Natl. Acad. Sci. 113, 4470\u20134475. https:\/\/doi.org\/10.1073\/pnas.1525349113 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"20749_CR56","doi-asserted-by":"publisher","unstructured":"Khan, F. et al. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J. Clin. Invest. 133. https:\/\/doi.org\/10.1172\/jci163446 (2023).","DOI":"10.1172\/jci163446"},{"key":"20749_CR57","doi-asserted-by":"publisher","first-page":"19542","DOI":"10.1038\/s41598-020-76657-3","volume":"10","author":"AP Landry","year":"2020","unstructured":"Landry, A. P., Balas, M., Alli, S., Spears, J. & Zador, Z. Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma. Sci. Rep. 10, 19542. https:\/\/doi.org\/10.1038\/s41598-020-76657-3 (2020).","journal-title":"Sci. Rep."},{"key":"20749_CR58","doi-asserted-by":"publisher","first-page":"e2219199120","DOI":"10.1073\/pnas.2219199120","volume":"120","author":"M Datta","year":"2023","unstructured":"Datta, M. et al. Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models. Proc. Natl. Acad. Sci. 120, e2219199120. https:\/\/doi.org\/10.1073\/pnas.2219199120 (2023).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"20749_CR59","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12195-024-00824-z","volume":"17","author":"A Burchett","year":"2024","unstructured":"Burchett, A., Siri, S., Li, J., Lu, X. & Datta, M. Novel 3-D macrophage spheroid model reveals reciprocal regulation of Immunomechanical stress and Mechano-Immunological response. Cell. Mol. Bioeng. 17, 329\u2013344. https:\/\/doi.org\/10.1007\/s12195-024-00824-z (2024).","journal-title":"Cell. Mol. Bioeng."},{"key":"20749_CR60","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis, C. D., Ferraro, G. B. & Jain, R. K. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat. Rev. Cancer. 20, 26\u201341. https:\/\/doi.org\/10.1038\/s41568-019-0205-x (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"20749_CR61","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","volume":"18","author":"PS Steeg","year":"2021","unstructured":"Steeg, P. S. The blood-tumour barrier in cancer biology and therapy. Nat. Rev. Clin. Oncol. 18, 696\u2013714. https:\/\/doi.org\/10.1038\/s41571-021-00529-6 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"20749_CR62","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.seizure.2014.06.015","volume":"23","author":"Y Yuan","year":"2014","unstructured":"Yuan, Y. et al. Survival analysis for valproic acid use in adult glioblastoma multiforme: A meta-analysis of individual patient data and a systematic review. Seizure 23, 830\u2013835. https:\/\/doi.org\/10.1016\/j.seizure.2014.06.015 (2014).","journal-title":"Seizure"},{"key":"20749_CR63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/sajc.sajc_188_17","volume":"7","author":"D Valiyaveettil","year":"2018","unstructured":"Valiyaveettil, D. et al. Effect of valproic acid on survival in glioblastoma: A prospective single-arm study. South. Asian J. Cancer. 7, 159\u2013162. https:\/\/doi.org\/10.4103\/sajc.sajc_188_17 (2018).","journal-title":"South. Asian J. Cancer"},{"key":"20749_CR64","doi-asserted-by":"publisher","first-page":"e69964","DOI":"10.1371\/journal.pone.0069964","volume":"8","author":"JE Hanson","year":"2013","unstructured":"Hanson, J. E. et al. SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition. PLoS One. 8, e69964. https:\/\/doi.org\/10.1371\/journal.pone.0069964 (2013).","journal-title":"PLoS One"},{"key":"20749_CR65","doi-asserted-by":"publisher","first-page":"103457","DOI":"10.1016\/j.redox.2024.103457","volume":"79","author":"KY Pham","year":"2025","unstructured":"Pham, K. Y. et al. HDAC6 inhibitor-loaded brain-targeted nanocarrier-mediated neuroprotection in methamphetamine-driven parkinson\u2019s disease. Redox Biol. 79, 103457. https:\/\/doi.org\/10.1016\/j.redox.2024.103457 (2025). https:\/\/doi.org\/https:\/\/doi.org\/","journal-title":"Redox Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20749-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20749-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20749-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:44:40Z","timestamp":1761039880000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20749-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20749"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-20749-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6573675\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36804"}}